Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04191421
Recruitment Status : Not yet recruiting
First Posted : December 9, 2019
Last Update Posted : January 21, 2020
Sponsor:
Collaborators:
Novartis
EUSA Pharma
Information provided by (Responsible Party):
Bassel El-Rayes, Emory University

Brief Summary:
This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the ability of tumors cells to grow and spread.

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8 Biological: Siltuximab Biological: Spartalizumab Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. Determine the recommended phase II dose for the combination of spartalizumab and siltuximab.

SECONDARY OBJECTIVES:

I. Define the toxicity profile of the combination of the recommended phase II dose of spartalizumab and siltuximab.

II. Evaluate the activity of the combination of spartalizumab and siltuximab in previously treated patients with pancreatic cancer.

EXPLORATORY OBJECTIVE:

I. Evaluate the effect of the combination on the immune profile in the serum and in tumor biopsies.

OUTLINE: This is a dose-escalation study of siltuximab.

Participants receive spartalizumab intravenously (IV) over 30 minutes on day 1 and siltuximab IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30, 60, 90, 120, and 150 days, then every 12 weeks thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Arm 1- (Phase I dose level 1)- Siltuximab 6 mg/Kg every 3 weeks and Spartalizumab 300mg every 3 weeks Arm 2- (Phase I dose level 2)- Siltuximab 11 mg/Kg every 3 weeks and spartalizumab 300 mg every 3weeks Arm 3 - (Phase I doe level 2a)- Siltuximab 9 mg/Kg every 3 weeks and spartalizumab 300 mg every 3weeks Arm 4- (Phase II)- Siltuximab RP2D determined in Arms 1 to 3 and spartalizumab 300 mg every 3weeks
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Siltuximab

Arm Intervention/treatment
Experimental: Treatment spartalizumab and siltuximab Phase I dose level 1
Arm 1 (Phase I dose level 1) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 6 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Biological: Siltuximab
Given IV
Other Names:
  • Anti-IL-6 Chimeric Monoclonal Antibody
  • cCLB8
  • CNTO 328
  • Sylvant

Biological: Spartalizumab
Given IV
Other Name: PDR001

Experimental: Treatment spartalizumab and siltuximab Phase I level 2
Arm 2 (Phase I dose level 2) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 11 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Biological: Siltuximab
Given IV
Other Names:
  • Anti-IL-6 Chimeric Monoclonal Antibody
  • cCLB8
  • CNTO 328
  • Sylvant

Biological: Spartalizumab
Given IV
Other Name: PDR001

Experimental: Treatment spartalizumab and siltuximab phase I level 2a
Arm 3 (Phase I dose level 2a) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 9 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Biological: Siltuximab
Given IV
Other Names:
  • Anti-IL-6 Chimeric Monoclonal Antibody
  • cCLB8
  • CNTO 328
  • Sylvant

Biological: Spartalizumab
Given IV
Other Name: PDR001

Experimental: Treatment spartalizumab and siltuximab phase II
Arm 4 (Phase II ) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab at dose determined in Arm 1 to 3 IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Biological: Siltuximab
Given IV
Other Names:
  • Anti-IL-6 Chimeric Monoclonal Antibody
  • cCLB8
  • CNTO 328
  • Sylvant

Biological: Spartalizumab
Given IV
Other Name: PDR001




Primary Outcome Measures :
  1. Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab [ Time Frame: Up to 6 weeks from study start ]
    Maximal tolerated dose (MTD )is defined as the dose at which less than one-third of the subjects experience a dose-limiting toxicity (DLT) in the first 6 weeks of treatment. A DLT is defined as an adverse event or abnormal laboratory value assessed as definitely at least possibly related to study treatment treatment related that occurs within the first 6 weeks. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading.


Secondary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: Up to 2 years from study start ]
    Overall response rate is defined as complete response (CR) + partial response (PR) in participants treated with siltuximab and spartalizumab and will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

  2. Response duration [ Time Frame: From treatment start until progression or death, assessed up to 2 years ]
    Will be assessed by RECIST 1.1.

  3. Progression-free survival [ Time Frame: From treatment start until progression or death, assessed up to 2 years ]
    Will be assessed by RECIST 1.1.

  4. Overall survival time [ Time Frame: From treatment start until progression or death, assessed up to 2 years ]
    Will be assessed by RECIST 1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cytological or histologic diagnosis and metastatic pancreatic adenocarcinoma disease that has failed at least one standard regimen such as gemcitabine nab-paclitaxel or folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX).
  • Patient must meet the following laboratory values at the screening visit:

    • Absolute neutrophil count ≥ 1.5 x 109/L
    • Platelets ≥ 75 x 109/L
    • Hemoglobin (Hgb) ≥ 9 g/dL
    • Serum creatinine < 1.5 mg/dL OR Creatinine Clearance ≥ 45 mL/min using Cockcroft-Gault formula
    • Total bilirubin ≤ 1.5 x ULN
    • Aspartate transaminase (AST) ≤ 2.5 x ULN, except for patients with liver metastasis, who may only be included if AST ≤ 5.0 x upper limit of normal (ULN)
    • Alanine transaminase (ALT) ≤ 2.5 x ULN, except for patients with liver metastasis, who may only be included if ALT ≤ 5.0 x ULN
  • Presence of measurable disease by RECIST criteria
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Written informed consent must be obtained prior to any screening procedures.
  • Normal ECG defined as the following:
  • Resting heart rate 50-90 bpm
  • QT corrected for HR using Fridericia's method (QTcF) at screening < 450 ms (male patients), < 460 ms (female patients)
  • Before enrollment, a woman must be either:

    • Not of childbearing potential: postmenopausal (> 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level > 40 IU/mL); permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy
    • Of childbearing potential and practicing (during the study and for 150 days after receiving the last dose of study agent) a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: eg, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that subject); true abstinence (when this is in line with the preferred and usual lifestyle of the subject)
    • Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active) a woman must begin a highly effective method of birth control, as described above.
  • A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at screening.
  • During the study and for 150 days after receiving the last dose of study agent, a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction.
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug.
  • Sign an informed consent document indicating that they understand the purpose of and procedures required for the study, are willing to participate in the study, and are willing and able to adhere to the prohibitions and restrictions specified in this protocol. Informed consent must be obtained before performing any study specific procedures.

Exclusion Criteria:

  • Prior exposure to agents targeting programmed cell death protein-1 (PD-1), PD-L1, IL-6 or the IL-6 receptor. Prior chemotherapy is allowed as long as adequate washout period of ≥ 4 weeks.
  • Any untreated central nervous system (CNS) lesion. However, patients are eligible if: a) all known CNS lesions have been treated with radiotherapy or surgery and b) patient remained without evidence of CNS disease progression ≥ 4 weeks after treatment and c) patients must be off corticosteroid therapy for ≥ 2 weeks.
  • Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
  • Systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date of first dose of study treatment. Note: Topical, inhaled, nasal and ophthalmic steroids are allowed.
  • Active, known or suspected autoimmune disease or a documented history of autoimmune disease Note: Patients with vitiligo, controlled type I diabetes mellitus on stable insulin dose, residual autoimmune-related hypothyroidism only requiring hormone replacement or psoriasis not requiring systemic treatment are permitted).
  • Allogenic bone marrow or solid organ transplant.
  • History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
  • Known history or current interstitial lung disease or non-infectious pneumonitis.
  • Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ.
  • Clinically significant infection, including known HIV or hepatitis C infection, or known hepatitis B surface antigen positivity.
  • Clinically significant ongoing infection.
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half-lives before enrollment (whichever is longer) or is currently enrolled in the treatment stage of an investigational study.
  • A woman who is pregnant or breast-feeding, or a woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within 150 days after the last dose of study agent.
  • Had hospitalization for infection or major surgery (eg, requiring general anesthesia) within 2 weeks before enrollment or have not fully recovered from surgery. Note: subjects with surgical procedures conducted under local anesthesia may participate.
  • History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease, including any of the following:

    • Recent myocardial infarction (within last 6 months)
    • Uncontrolled congestive heart failure
    • Unstable angina (within last 6 months)
    • Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third degree atrioventricular block (AV) block without a pacemaker)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04191421


Contacts
Layout table for location contacts
Contact: Bassel El-Rayes, MD 404-778-2670 bassel.el-rayes@emoryhealthcare.org

Locations
Layout table for location information
United States, Georgia
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
Contact: Shabnam Montazeri    404-686-0242    shabnam.montazeri@emory.edu   
Contact: Allyson Anderson    404-686-0239    allyson.anderson@emory.edu   
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Contact: Sheena Abraham    404-778-2670    sheena.abraham@emory.edu   
Contact: Tyra Gaines    404-778-3308    tgaines3@emory.edu   
Emory Saint Joseph's Hospital
Atlanta, Georgia, United States, 30342
Contact: Alicia Escobar    678-843-7029    alicia.m.escobar@emory.edu   
Contact: Lauryn Taylor    678-843-7544    lauryn.a.taylor@emory.edu   
Sponsors and Collaborators
Emory University
Novartis
EUSA Pharma
Investigators
Layout table for investigator information
Principal Investigator: Bassel El-Rayes, MD Emory University

Layout table for additonal information
Responsible Party: Bassel El-Rayes, Principal Investigator, Emory University
ClinicalTrials.gov Identifier: NCT04191421    
Other Study ID Numbers: IRB00105616
NCI-2018-01793 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Winship4463-18 ( Other Identifier: Emory University Hospital/Winship Cancer Institute )
First Posted: December 9, 2019    Key Record Dates
Last Update Posted: January 21, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Siltuximab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs